TY - JOUR
T1 - Management of acute and refractory Kawasaki disease
AU - Tacke, Carline E.
AU - Burgner, David
AU - Kuipers, Irene M.
AU - Kuijpers, Taco W.
PY - 2012
Y1 - 2012
N2 - Expert Rev. Anti Infect Ther. 10(10), 1203-1215 (2012) Acute Kawasaki disease (KD) is treated with high-dose intravenous immunoglobulin (IVIG), which is proven to decrease the incidence of coronary artery aneurysms from 25% to less than 5%. Aspirin is also given, although the evidence base is less secure. There is increasing evidence for steroid therapy as adjunctive primary therapy with IVIG, especially in Asian children. Approximately 10-30% of patients fail to respond to the initial IVIG and are at increased risk of coronary artery aneurysms. The optimal treatment for IVIG-nonresponsive KD remains controversial. Management options include further dose(s) of IVIG, corticosteroids, TNF-alpha blockade, cyclosporin A, anti-IL-1 and anti-CD20 therapy. In this article, the authors review the current evidence for treatment of acute KD and discuss options for IVIG nonresponders
AB - Expert Rev. Anti Infect Ther. 10(10), 1203-1215 (2012) Acute Kawasaki disease (KD) is treated with high-dose intravenous immunoglobulin (IVIG), which is proven to decrease the incidence of coronary artery aneurysms from 25% to less than 5%. Aspirin is also given, although the evidence base is less secure. There is increasing evidence for steroid therapy as adjunctive primary therapy with IVIG, especially in Asian children. Approximately 10-30% of patients fail to respond to the initial IVIG and are at increased risk of coronary artery aneurysms. The optimal treatment for IVIG-nonresponsive KD remains controversial. Management options include further dose(s) of IVIG, corticosteroids, TNF-alpha blockade, cyclosporin A, anti-IL-1 and anti-CD20 therapy. In this article, the authors review the current evidence for treatment of acute KD and discuss options for IVIG nonresponders
U2 - https://doi.org/10.1586/ERI.12.101
DO - https://doi.org/10.1586/ERI.12.101
M3 - Review article
C2 - 23199405
SN - 1478-7210
VL - 10
SP - 1203
EP - 1215
JO - Expert Review of Anti-Infective Therapy
JF - Expert Review of Anti-Infective Therapy
IS - 10
ER -